drugset / Trial / NCT00208208
Geodon (Ziprasidone) for Posttraumatic Stress Disorder
RandomizedParallel-groupDouble-blindDiagnostic
Summary
Atypical antipsychotics have shown promise in the treatment of depression and anxiety, which are prominent symptoms of PTSD. The profile of the atypical antipsychotic, ziprasidone (Geodon), suggests possible anxiolytic and antidepressant properties. This research will assess the potential effectiveness of Geodon in civilian men and women who suffer from severe PTSD. Response to ziprasidone or placebo will be measured by Clinician Administered PTSD Scale (CAPS) and Treatment Outcomes PTSD Scale (TOP-8).
Timeline
- Start
- 2002-12
- Primary completion
- —
- Completion
- 2005-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ziprasidone | Small molecule | — | — |